A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
27 10 2021
27 10 2021
Historique:
received:
01
07
2021
accepted:
06
10
2021
entrez:
28
10
2021
pubmed:
29
10
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Rapid development of COVID-19 vaccines has helped mitigating SARS-CoV-2 spread, but more equitable allocation of vaccines is necessary to limit the global impact of the COVID-19 pandemic and the emergence of additional variants of concern. We have developed a COVID-19 vaccine candidate based on Newcastle disease virus (NDV) that can be manufactured at high yields in embryonated eggs. Here, we show that the NDV vector expressing an optimized spike antigen (NDV-HXP-S) is a versatile vaccine inducing protective antibody responses. NDV-HXP-S can be administered intramuscularly as inactivated vaccine or intranasally as live vaccine. We show that NDV-HXP-S GMP-produced in Vietnam, Thailand and Brazil is effective in the hamster model. Furthermore, we show that intramuscular vaccination with NDV-HXP-S reduces replication of tested variants of concerns in mice. The immunity conferred by NDV-HXP-S effectively counteracts SARS-CoV-2 infection in mice and hamsters.
Identifiants
pubmed: 34707161
doi: 10.1038/s41467-021-26499-y
pii: 10.1038/s41467-021-26499-y
pmc: PMC8551302
doi:
Substances chimiques
Spike Glycoprotein, Coronavirus
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6197Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)
ID : INV-021239
Informations de copyright
© 2021. The Author(s).
Références
Lancet Microbe. 2021 Jul;2(7):e283-e284
pubmed: 33846703
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
J Virol. 2008 Mar;82(6):2692-8
pubmed: 18199643
N Engl J Med. 2021 Mar 8;384(15):1466-1468
pubmed: 33684280
Curr Protoc Microbiol. 2010 May;Appendix 4:4I
pubmed: 20440679
NPJ Vaccines. 2017 Dec 4;2:33
pubmed: 29263888
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Nat Immunol. 2011 Jun;12(6):509-17
pubmed: 21739679
Vaccine. 2008 Jan 24;26(4):522-31
pubmed: 18093698
Vaccine. 2021 Jan 15;39(3):512-520
pubmed: 33341308
Vaccine. 2018 Jun 18;36(26):3842-3852
pubmed: 29779923
Future Microbiol. 2012 Mar;7(3):347-67
pubmed: 22393889
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
Emerg Microbes Infect. 2020 Dec;9(1):2433-2445
pubmed: 33073694
EBioMedicine. 2020 Dec;62:103132
pubmed: 33232870
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9788-93
pubmed: 17535926
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):
pubmed: 33688034
Lancet. 2021 Jun 5;397(10290):2148-2149
pubmed: 34090600
J Virol. 1999 Jan;73(1):251-9
pubmed: 9847328
N Engl J Med. 2021 Jun 17;384(24):2352-2354
pubmed: 33826819
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8203-8
pubmed: 16717196
Vaccines (Basel). 2020 Dec 17;8(4):
pubmed: 33348607
Biomedicines. 2016 Jul 20;4(3):
pubmed: 28536382
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Nat Med. 2014 Feb;20(2):143-51
pubmed: 24412922
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Nature. 1988 Jul 21;334(6179):255-8
pubmed: 2456466
mSphere. 2017 Mar 29;2(2):
pubmed: 28405630
EBioMedicine. 2019 Nov;49:96-105
pubmed: 31676387
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
J Integr Agric. 2017 Oct;16(10):2264-2273
pubmed: 32288953
J Vis Exp. 2013 Oct 11;(80):
pubmed: 24145366
J Virol. 2001 Dec;75(23):11868-73
pubmed: 11689668
Methods Mol Biol. 2020;2058:133-154
pubmed: 31486036
Methods Mol Biol. 2017;1494:15-27
pubmed: 27718183
Vaccines (Basel). 2020 Aug 24;8(3):
pubmed: 32846910
J Virol. 2011 Mar;85(5):2235-46
pubmed: 21159873
J Virol. 2009 Jan;83(2):584-97
pubmed: 19004953